Emerging and Innovative Biotherapeutics to Address Unmet Medical Needs

The Therapeutics Stream at the PEGS Summit Boston brings together three dynamic programs showcasing the diversity of approaches driving the next generation of drug innovation. Biologics for Autoimmune Diseases will highlight novel strategies across musculoskeletal, skin, and gut disorders, alongside cutting-edge modalities and translational tools that are reshaping treatment possibilities for complex immune-mediated conditions. Frontiers in Radiopharmaceutical Therapies will showcase the latest advances driving this rapidly expanding field, from novel targets and isotope selection, to dosimetry and next generation theranostic advances revolutionizing patient care. And the new Emerging Peptide Therapeutics track will spotlight the revival of peptide drug discovery, featuring advances in engineering, design, and therapeutic applications including half-life extended peptides and GLP-1 agonists. Together, these programs offer a comprehensive view of the therapeutic innovations poised to change patient care.

Conferences Include:

May 11-12

Biologics for Autoimmune Diseases

May 12-13

Frontiers in Radiopharmaceutical Therapy

May 14-15

Emerging Peptide Therapeutics

Keynote and Features Presentations:

Induced Proximity Strategies for Treatment of Autoimmune Diseases
Scott Lesley, PhD, President and CSO, InDuPro; former Vice President, Discovery Biologics, Merck

Novel Applications in Radiopharmaceutical Therapy: Routes of Delivery and Therapeutic Combinations
Zachary S. Morris, PhD, MD, Department Chair and Endowed Professor of Human Oncology, University of Wisconsin Madison

The Next Generation of ADCs or a Completely Different Technology?
Geoffrey B. Johnson, MD, PhD, Physician, Nuclear Medicine, Mayo Clinic Comprehensive Cancer Care

Peptide Therapeutics in Tissue Regeneration and Disease: Agonist and Antagonist Strategies
Rami N. Hannoush, PhD, Venture Partner, Versant Ventures; former Group Leader, Early Discovery Biochemistry, Genentech, Inc.

2026 PROGRAMS

View By:

• Display of Biologics
• Engineering Antibodies
• Machine Learning for Protein Engineering

• Antibodies for Cancer Therapy
• Emerging Targets for Oncology & Beyond
• Driving Clinical Success in Antibody-Drug Conjugates

• TS: Intro to Multispecific Antibodies
• Advancing Multispecific Antibodies
• Engineering Bispecific and Multispecific Antibodies

• Emerging T Cell Engagers
• Advances in Immunotherapy
• Next-Generation Immunotherapies

• Difficult-to-Express Proteins
• Optimizing Protein Expression
• Maximizing Protein Production Workflows

• ML and Digital Integration in Biotherapeutic Analytics
• Biophysical Methods
• Characterization for Novel Biotherapeutics

• TS: Intro to Immunogenicity
• Predicting Immunogenicity with AI/ML Tools
• TS: Bioassay Development and Analysis

• Biologics for Autoimmune Diseases
• Frontiers in Radiopharmaceutical Therapy
• Emerging Peptide Therapeutics

• ML and Digital Integration in Biotherapeutic Analytics
• Predicting Immunogenicity with AI/ML Tools
• Machine Learning for Protein Engineering